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Abstract
The EGF-related protein EFEMP1 (EGF-containing fibu-
lin-like extracellular matrix protein 1) has been shown to
promote tumor growth in human adenocarcinoma. To
understand the mechanism of this action, the signal
transduction activated upon treatment with this protein
has been investigated. We show that EFEMP1 binds EGF
receptor (EGFR) in a competitive manner relative to epi-
dermal growth factor (EGF), implicating that EFEMP1 and
EGF share the same or adjacent binding sites on the
EGFR. Treatment of pancreatic carcinoma cells with puri-
fied EFEMP1 activates autophosphorylation of EGFR at
the positions Tyr-992 and Tyr-1068, but not at the posi-
tion Tyr-1048. This signal is further transduced to phos-
phorylation of Akt at position Thr-308 and p44/p42
MAPK (mitogen-activated protein kinase) at positions
Thr-202 and Tyr-204. These downstream phosphorylation
events can be inhibited by treatment with the EGFR
kinase inhibitor PD 153035. The observed signal trans-
duction upon treatment with EFEMP1 can contribute to
the enhancement of tumor growth shown in pancreatic
carcinoma cells overexpressing EFEMP1.
Keywords: downstream signaling; EFEMP1; EGF
receptor (EGFR); epidermal growth factor (EGF);
phosphorylation.
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Introduction
Fibulins are a family of five extracellular matrix proteins
characterized by tandem arrays of epidermal growth
factor (EGF)-like domains and a C-terminal fibulin-type
module. They are widely distributed and often associated
with vasculature and elastic tissues (Kobayashi et al.,
2007). EFEMP1 (EGF-containing fibulin-like extracellular
matrix protein 1) also known as fibulin-3 plays an im-
portant role in many physiological processes including
pathogenesis of degenerative eye diseases. Age-related
macular degeneration (AMD) is the most common cause
of vision loss in developed countries. EFEMP1 R345W
mutant mice develop deposits of material between
Bruch’s membrane and the retinal pigment epithelium,
which resemble basal deposits in patients with AMD (Fu
et al., 2007). The same mutation is responsible for the
eye disease Malattia Leventinese, indicating that
EFEMP1 might be important in drusen formation. Wild
type EFEMP1 is a secreted protein, whereas mutant
EFEMP1 R345W is misfolded, secreted inefficiently, and
retained within cells (Marmorstein et al., 2002). Data
obtained on EFEMP1-/- mice have confirmed the hypoth-
esis about the role of misfolding in manifestation of
symptoms of this disease. No apparent macular degen-
eration associated defects were found in these mice,
suggesting that loss of fibulin-3 function is not the mech-
anism by which the mutation in EFEMP1 causes macular
degeneration (McLaughlin et al., 2007). Nevertheless,
EFEMP1 knockin mice carrying disease-associated
mutation in the murine EFEMP1 gene reconstitute the
most important histopathologic symptoms of both
Malattia Leventinese and AMD (Marmorstein et al., 2007).
EFEMP1 also participates in other processes such as
regulation of body weight or behavioral control. A C/T
polymorphism of the EFEMP1 gene in the position
56022960 of chromosome 2 is one of the identified
variants influencing adult human height (Weedon et al.,
2008). Transcriptional analysis of 11 post-mortem brain
tissues of suicide victims compared with 10 non-psychi-
atric controls revealed that changes on EFEMP1 expres-
sion could be implicated in the etiology of human suicidal
behavior (Thalmeier et al., 2008). These data suggest that
EFEMP1 is subject to different cellular regulation
mechanisms.
In the current study, we demonstrated an interaction
of EFEMP1 of wild type with EGF receptor (EGFR) fol-
lowed by the activation of downstream signaling in a
human pancreatic adenocarcinoma cell line. EFEMP1 is
for the first time shown as a functional ligand of the EGFR
activating Akt- and mitogen-activated proteinkinase
(MAPK)-signal transduction.
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Figure 1 Expression of EFEMP1 in FG and L3.6pl cells.
Results of Western blotting performed using an anti-EFEMP1
antibody and a b-actin antibody as a loading control. ‘F’ denotes
cell extract prepared from FG cells and ‘L’ denotes the cell
extract prepared from L3.6pl cells.
Results
Expression of EFEMP1 and other relevant genes
in pancreatic carcinoma cells
Our previous Affymetrix analysis of transcriptome of
L3.6pl cells vs. FG cells has revealed that EFEMP1
belongs to the group of the genes being upregulated in
the aggressive, highly metastatic and angiogenic pancre-
atic carcinoma cell line L3.6pl. Our quantitative real-time
RT-PCR data have fully confirmed these data (Seeliger et
al., 2009). The transcription results by themselves, how-
ever, do not reveal biological relevance. Therefore, we
investigated expression of this gene on the protein level
in both previously studied cell lines via Western blotting
using anti-EFEMP1 specific antibody. Our results show
that the expression of EFEMP1 is upregulated on the pro-
tein level as well in the cell line L3.6pl (Figure 1). We have
shown that elevated expression of EFEMP1 is responsi-
ble for at least the part of differential phenotype of L3.6pl
vs. FG cells (Seeliger et al., 2009).
RT-PCR data revealed no significant differential gene
expression of EGFR in both investigated cell lines deter-
mined on both RNA and protein levels (Figure 2). Our
FACE (Fast Activated Cell-based ELISA) results con-
firmed the results on total EGFR content obtained by
Western blotting and also demonstrated significant
differences in phosphorylation of EGFR at the position
of Tyr-992 in both investigated cell lines.
EGF content and production was also investigated.
The growth medium containing 10% fetal calf serum
(FCS, batch: S0115, Biochrom, Berlin, Germany) does
not contain EGF in an amount detectable by ELISA. RT-
PCR data revealed weak transcription of the EGF gene
in both investigated cell lines. The results of EGF ELISA
with conditioned media reveal that both investigated cell
lines produce only 3 pg of EGF per ml of medium and
per million of cultivated cells during 48 h. These data
show that the EFEMP1 protein, being described for
the first time in the context of cancer, might play an
important role in carcinogenesis. Therefore, we investi-
gated the function of this protein in terms of signal
transduction.
Sequence of EFEMP1 L3.6pl-cDNA
Our results have shown that the cells overexpressing
EFEMP1 exhibit elevated proangiogenic properties
(Seeliger et al., 2009). It has been previously described
that the mutation R345W causes poor secretion of
EFEMP1 protein following upregulation of VEGF ex-
pression (Roybal et al., 2005). Therefore, cDNA has been
amplified by PCR and sequenced. Our results show that
both cell lines, L3.6pl and FG, express wild type EFEMP1
gene coding for arginine in the position 345.
Interaction of EFEMP1 with EGFR
The multiple sequence alignment revealed significant
similarity of amino acid sequences between 1207 amino
acid long form of EGF as the primary ligand of EGFR and
EFEMP1 (Figure 3). Hot spot of similarity is concentrated
in the amino acid sequence position 53 creating the
structure of soluble EGF interacting with its receptor.
Therefore, we addressed the issue of a possible inter-
action between EFEMP1 (molecular mass of 54 kDa) and
EGFR. Following immunoprecipitation using anti-EGFR
antibody, the band corresponding to the protein with an
apparent molecular mass of approximately 54 kDa was
detected in the case of both extracts prepared from FG
or L3.6pl cells, respectively. The band was specifically
identified by anti-EFEMP1 antibody and was dependent
on the presence of anti-EGFR antibody during immuno-
precipitation (see control without anti-EGFR antibody on
Figure 4). The presented data show that EFEMP1 has the
ability to interact with EGFR.
Competition between EFEMP1 and EGF on binding
to its receptor
To investigate whether EFEMP1 competes with EGF for
binding to its receptor, the described immunoprecipita-
tion experiment was repeated after treatment of the
L3.6pl cells with EGF or with bovine serum albumin (BSA)
as an unspecific control, respectively. The amount of cell
extract used for immunoprecipitation was normalized to
the same protein concentration. Additionally, the amount
of immunoprecipitated EGFR was tested by Western
blotting using anti-EGFR antibody. Our data (Figure 5)
showed that the amount of immunoprecipitated EFEMP1
after treatment with anti-EGFR antibody is significantly
reduced in competition with EGF, whereas the amount of
immunoprecipitated EGFR is comparable.
Phosphorylation of EGFR induced by EFEMP1
Interaction between EGF and its receptor leads to an
activation of receptor self-phosphorylation (Koland et al.,
1990). Therefore, we investigated phosphorylation of
EGFR in the pancreatic cell line L3.6pl treated with puri-
fied EFEMP1 protein. Western blotting using the extract
of cells treated with 50 ng/ml EFEMP1 showed that this
treatment activates phosphorylation of EGFR at the posi-
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Figure 2 Expression of EGFR (epidermal growth factor receptor) in FG or L3.6pl cells respectively.
(A) Western blotting. Proteins from cell extracts prepared from both cell lines were subjected to Western blotting and detected using
the anti-total-EGFR antibody. Loading was controlled using anti-b-actin antibody. ‘F’ denotes FG cells and ‘L’ denotes L3.6pl cell
line. (B) Transcription of relevant gene in FG or L3.6pl cells, respectively, analyzed by RT-PCR. Total RNA prepared from both untreated
cell lines was subjected to single step RT-PCR. Its products were separated in the agarose gel. ‘F’ denotes FG cells and ‘L’ denotes
L3.6pl cell line. Used primer sets are indicated. (C) Results of FACE in cell Western blot analysis for Y992 EGFR. The same amount
of FG and L3.6pl cells were serum-starved for 24 h and then activated with FCS or EGF, or were left untreated. Colorimetric signal
proportional to concentration of EGFR or to its activation on Tyr-992, respectively, was recorded and normalized to the signal obtained
after crystal violet staining proportional to the cell number. Relative values are depicted; treatments and used cell lines are indicated.
Figure 3 Results of the multiple sequence alignment.
(A) Shown in the form of a phylogenetic tree. The sequences of the EGF receptor ligands were compared using DNA* MegAlign
software. The similarity between the sequences of EFEMP1 and EGF is shown. (B) Lipman Pearson protein sequence alignment
EFEMP1 and EGF. Analysis was performed using DNA* MegAlign software. Consensus sequence and amino acid similarity between
both sequences are indicated.
tions of Tyr-992 and Tyr-1068. There was no significant
difference between phosphorylation of Tyr-1048 in EGFR
in the samples treated or untreated with EFEMP1 (Figure
6). Probing of the membrane with antibody identifying the
total amount of EGFR showed equal gel-loading.
Effect of EFEMP1 treatment on Akt and MAPK
signaling
Because our data showed that EFEMP1 has the ability
to bind EGFR and that this binding triggers its phospho-
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Figure 4 Co-immunoprecipitation of EFEMP1 with the EGF
receptor.
Anti-EGFR antibody was used for immunoprecipitation of the
same protein amount of the cell extract made on FG or L3.6pl
cells, respectively. The immunoprecipitate was probed with anti-
EFEMP1 antibody using immunoblotting. The positive band cor-
responds to the protein being identified by the antibody, and its
electrophoretic mobility corresponds to a molecular mass of
54 kDa for EFEMP1. The molecular masses according to Magic
XP Western marker are indicated. FG IP denotes the proteins
immunoprecipitated from FG cell extract and L3.6pl IP denotes
the proteins immunoprecipitated from L3.6pl cell extract. As a
negative control, a sample in the absence of the anti-EGFR
antibody (noAb) was used.
Figure 5 Competition between EGF and EFEMP1 on binding
to EGFR.
Immunoprecipitation using anti-EGFR antibody was repeated
after treatment with 50 ng/ml EGF or with irrelevant arbitrary
protein, BSA. Treatment with EGF diminishes the yield of the
immunoprecipitated EFEMP1 probably owing to competition
between EGF and EFEMP1 binding to EGFR. The membrane
was reprobed with the antibody identifying the total immunopre-
cipitated EGFR as a loading control. BSA denotes the cell
extract prepared on cells treated with BSA and EGF denotes the
cell extract prepared on cells treated with EGF.
Figure 6 Autophosphorylation of EGFR on treatment with
EFEMP1.
Biological relevance of EFEMP1 binding on the EGFR was dem-
onstrated by detection of autophosphorylation of EGFR on treat-
ment with 50 ng/ml of purified EFEMP1 or with the same amount
of arbitrary protein BSA used as a negative control. Phospho-
rylation of EGFR on the sites Tyr-992, Tyr-1048, and Tyr-1068 on
treatment with EFEMP1 was monitored by immunoblotting using
appropriate anti-phospho-EGFR antibody. The membrane was
also probed with the antibody identifying total EGFR as a loading
control.
Figure 7 Effect of EFEMP1 treatment on downstream MAPK
and Akt signaling.
Activation of MAPK- and Akt-signal transduction on treatment
of L3.6pl cells with EFEMP1 was demonstrated by immunoblot-
ting with anti-phospho-p44/p42 MAPK (Erk) Thr-202, Tyr-204,
and phospho-Akt Thr-308 antibodies. Treatment of L3.6pl cells
leads to activation of p44/p42 MAPK in positions Thr-202 and
Tyr-204, and to activation of Akt in position Thr-308 as well. This
effect can be reversed on treatment with EGFR inhibitor
PD135035. The membrane was probed with anti-b-actin, total
Akt, and total MAPK antibodies for a loading control. Treatments
and the antibodies are indicated.
rylation, we investigated activation of downstream tar-
gets: Akt and Erk2. The extract prepared from L3.6pl
cells treated with 50 ng/ml EFEMP1 or with the same
concentration of BSA were normalized to the same
protein concentrations and were subjected to Western
blotting with phosphorylation-sensitive antibodies aga-
inst Akt and Erk2. Our data show that treatment of L3.6pl
cells with EFEMP1 activates the MAPK pathway, as
demonstrated by phosphorylation of Erk2 proteins p42
and p44 in positions Tyr-202 and Tyr-204, respectively
(Figure 7). Similarly, EFEMP1 treatment activates phos-
phorylation of Akt in position Thr-308 which has been
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demonstrated via immunoblotting using appropriate anti-
phospho-Akt antibody.
Treatment with EGFR inhibitor PD153035
If phosphorylation of downstream proteins such as Akt
and Erk2 is caused by the activation of EGFR signaling
upon treatment with EFEMP1, inhibition of EGFR activity
should remove this effect. To test this hypothesis, L3.6pl
cells were treated with 50 ng/ml EFEMP1 in combination
with the EGFR inhibitor PD153035 (2 mmol/ml) or with
50 ng/ml EFEMP1 alone. Cell extracts were normalized
to the same protein concentration. Data obtained after
Western blotting using anti-phospho-Akt (Thr-308) anti-
body and anti-phospho-p44/42 MAPK (Thr-202/Tyr-204)
show that the inhibition of EGFR via PD153035 abro-
gates activation of Akt and Erk2 after EFEMP1 treatment.
These data suggest that the activation of Akt- and
MAPK-signal transduction pathways is mediated through
the EGFR-signaling pathway.
Discussion
Overexpression of EFEMP1 in highly metastatic
pancreatic carcinoma cells
Our data show that EFEMP1 is overexpressed in highly
metastatic and proangiogenic cell line L3.6pl (Bruns et
al., 1999) in comparison with its less metastatic maternal
cell line FG. Overexpression has been observed on both
the transcriptional and translational levels (Seeliger et al.,
2009; Figure 1). Interestingly, our Affymetrix analysis, pre-
viously published data (Nakamura et al., 2007; Seeliger
et al., 2009) as well as our RT-PCR and Western blotting
data do not exhibit significant differences in gene expres-
sion on the transcription and translation levels (Figure 1).
At the same time, differential activation of EGFR via
phosphorylation of Tyr-992 was demonstrated (Figure
2C). Our previously published data (Bruns et al., 2000)
demonstrated that the activation of EGFR plays an
important role in growth of tumors initiated by implanta-
tion of L3.6pl cells into nude mice. Because the growth
medium does not contain any EGF and cells produce
very little of this growth factor, EGFR activation observed
in a cell culture has to be dependent on an activation of
the receptor via alternative ligands or via crosstalk with
other cell signaling. We have previously demonstrated
that EFEMP1 is upregulated in L3.6pl cells (Seeliger et
al., 2009). Therefore, we assume that EFEMP1 contrib-
utes at least partially to the establishment of the aggres-
sive phenotype of these cells. Presented data lead to
the hypothesis that the effect of EFEMP1 on tumori-
genesis could be mediated via modulation of EGFR
signaling.
Binding of EFEMP1 to EGFR
Based on the primary structure of EFEMP1, the protein
belongs to the family of the proteins bearing the EGF
domain. Therefore, we compared sequences of all known
EGFR-binding proteins with the EFEMP1 sequence using
the ClustalV algorithm. Of all known EGFR-binding pro-
teins EFEMP1 has the highest homology to EGF (Figure
3A). Sequence alignment demonstrated that homology is
focused on the hot spot (Figure 3B), which is important
for binding of EGF to its receptor classified by X-ray crys-
tallographic data (Ogiso et al., 2002). Replacements of
Ile23 with Ala, Val, Leu, Phe, Trp, etc., have shown that
Ile23 of EGF is requisite for tight binding with the receptor
(Koide et al., 1992). The EGF Ile23-binding site, formed
by the side chains of Leu14, Tyr45 and Leu69 of EGFR,
has a shape roughly complementary to that of the Ile side
chain. The residues 31–33 of EGF form a short parallel
b-sheet important for interaction with EGFR (Ogiso et al.,
2002). The residues 31 and 33 of EGF are identical with
their corresponding amino acids 199 and 201 of EFEMP1
(Figure 3B). Asn32 of EGF is in EFEMP1 substituted with
similar amino acid Gln200. In addition, the Gln16 side
chain of EGFR creates hydrogen bonds with the Asn32
side chain of EGF (Ogiso et al., 2002). In this context, the
replacement of Asn32 by Asp significantly reduced the
receptor binding activity of EGF, but its replacement by
His, which can mimic Asn with regard to the hydrogen
donor activity, did not (Koide et al., 1992). Features of
Gln are more similar to Asn than features of His. Obvi-
ously, EFEMP1 contains appropriate amino acids in posi-
tions important for binding with EGFR.
Based on these facts we assumed that EFEMP1 could
belong to the EGFR ligand group. This hypothesis was
confirmed by immunoprecipitation experiments. Only in
the presence of anti-EGFR antibody, a protein with an
apparent molecular mass of 55 kDa and being specifi-
cally identified by anti-EFEMP1 antibody (Figure 4) can
be selectively co-immunoprecipitated. The molecular
mass of EFEMP1 according to its amino acid sequence
is 54 640 Da.
Because on the one hand EFEMP1 binds EGFR, and
on the other hand it is homologous to EGF at its EGFR-
binding interface, we assumed that both ligands might
bind to the same region of the receptor. Then EFEMP1
and EGF would compete for binding to the same recep-
tor. Therefore, we repeated the same immunoprecipita-
tion experiment with the cells pretreated with the
potential competitor, EGF. In fact, yield of EFEMP1 immu-
noprecipitated in the presence of added EGF was
diminished in comparison with the yield of EFEMP1
immunoprecipitated using the control cell extract pre-
pared on the cells treated with an arbitrary protein, BSA.
The results show that EFEMP1 and EGF share the same
EGFR region for their binding.
Activation of autophosphorylation on treatment
with EFEMP1
It has been previously shown that interaction of EGFR
with its ligands leads to the activation of autophospho-
rylation of the receptor at specific amino acids (Koland
et al., 1990). This action is accompanied by the activation
of downstream signaling and has been observed not only
on binding of EGF but also on binding of other EGF
ligands such as HB-EGF (Yin and Yu, 2009). Therefore,
the phosphorylation pattern of EGFR on treatment with
the purified EFEMP1 was investigated. Basal level of
phosphorylation of EGFR in absence of EFEMP1 was
determined and the treatment with BSA was used as a
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 07.11.13 15:14
1298 P. Camaj et al.
Article in press - uncorrected proof
control. Immunodetection using site-specific anti-phos-
pho-antibodies revealed that EGFR is specifically phos-
phorylated in the positions Tyr-992 and Tyr-1068 on
treatment with purified EFEMP1. The treatment of L3.6pl
cells with EFEMP1 does not affect autophosphoryla-
tion of EFGR in the position Tyr-1048. This means that
EFEMP1 binding does not activate the interaction with
Grb2 and therefore inhibition of the Ras-signaling and
proteasomal degradation of EFGR are not activated
(Rojas et al., 1996). Activation of EGFR autophosphory-
lation at the positions Tyr-992 and Tyr-1068 shows that
EFEMP1-based signal could be further transduced
toward MAPK and Akt activation (Zhang et al., 2002).
Activation of the downstream signaling
To investigate relevance of EFEMP1-binding on EFGR for
downstream signaling, we treated L3.6pl cells with puri-
fied EFEMP1 or with BSA as unspecific control, respec-
tively. Both cell extracts were subjected to Western
blotting using antibodies specifically identifying activated
forms of downstream EGFR-signaling targets deduced
according to identified pattern of autophosphorylation
induced by EFEMP1. Results suggested that signals
caused by EFEMP1-binding to EGFR are transduced
further to phosphorylation of downstream effectors. It
has been previously shown that stimulation of the pan-
creas carcinoma cells with EGF or FCS leads to the acti-
vation of ERK1 (extracellular regulated proteinkinase 1)
and p42 MAPK. MEK-1 inhibitor PD98059 abolished
EGF- and FCS-induced MAPK activation (Giehl et al.,
2000). EGF treatment of human Panc-48 adenocarcino-
ma cells activated Akt and Erk pathways. At the same
time, the blockade of the phosphatidylinositol-3 kinase/
Akt and MAPK/Erk abrogated the EGF-induced down-
stream signaling (Parikh et al., 2003; Yip et al., 2008).
Therefore, EFEMP1 activation of the downstream MAPK-
and Akt- signaling in the presence or absence of inhibitor
of the EGFR autophosphorylation, PD153035 (Fry et al.,
1994), was investigated. The results show that both Akt-
and MAPK-signal transduction pathways can be activat-
ed in the form of Akt phosphorylation in the position
Thr-308 and p42/p44 MAPK phosphorylation in the posi-
tions Thr-202 and Tyr-204, on treatment of the L3.6pl
cells with purified EFEMP1 (Figure 7). This activation
could be abrogated via the treatment with inhibitor of the
EGFR autophosphorylation. These data indicate that the
kinase activity of EGFR is essential for the transduction
of the EFEMP1 signal downstream toward activation of
Akt and MAPK pathways.
Biological relevance of binding EFEMP1 to EGFR
for pancreas carcinoma cells
Our study shows specific activation of Akt and MAPK
pathways under treatment with the protein EFEMP1
upregulated in in vivo selected highly metastatic pancre-
as carcinoma cell lines relative to their low metastatic
unselected counterpart. Using stable EFEMP1 transfec-
tants, we have shown that overexpression of this gene
causes enhanced tumor growth, metastasis and angio-
genesis in vivo (Seeliger et al., 2009). These data dem-
onstrate that upregulation of EFEMP1 in L3.6pl cells is at
least co-responsible for the enhancement of angioge-
nesis and metastasis rates occurring during the in vivo
selection leading to the transformation of less aggressive
cells FG to very highly aggressive cells L3.6pl. These
effects could be caused by an additional activation of
EGFR as a result of EFEMP1 binding followed by down-
stream Akt and MAPK activation. In some situations both
EGFR and EFEMP1, as one of its ligands, are regulated
simultaneously. The expression levels of EGFR and
EFEMP1 of human coronary artery endothelial cells are
downregulated under the exposition to laminar shear
stress (Chu and Peters, 2008).
Akt- and MAPK-signal transduction is an important
mediator of several cellular fates including growth,
proliferation and survival in several tissues including pan-
creatic tumors (Takeda et al., 2004; Schonleben et al.,
2007). Activation of the tumor growth as a result of EGF-
signaling transduced via MAPK or Akt activation is a
more general scenario present in several cell types (Wal-
ker et al., 1998; Schmitz et al., 2008). Net cell growth is
a result of a shift in the equilibrium between cell prolif-
eration and cell death. EGF-induced MAPK activation in
the BaF/3 cells inhibits apoptosis but does not influence
proliferation (Walker et al., 1998).
PI3K (phosphatidyl-inositol-3 kinase) and Akt mediate
survival and proliferative signals, allowing the cells to
escape apoptosis in various human cancers. PI3K inhi-
bition significantly enhances the antiproliferative and
proapoptotic effects of TNFa in both pancreas carcinoma
cell lines Panc-1 and MiaPaCa-2 (Shah et al., 2001; Yao
et al., 2002). In patients, 63–70% of the pancreas tumors
overexpress phosphorylated Akt (Semba et al., 2003).
Pancreatic cancer cells treated with PI3K inhibitor,
LY294002, underwent G1 arrest, which was associated
with the dephosphorylation of the ppRB protein, a
decrease in the protein expression of cyclin D and cyclin
E, and their activating partners Cdk2, 4, and 6 with simul-
taneous accumulation of P27/Kip1. This accumulation by
Akt inactivation could induce the cell cycle arrest in the
G1 phase and suggest that the PI3K-Akt pathway plays
an important role in cell proliferation in human pancreatic
ductal carcinoma cells (Takeda et al., 2004).
Mitogen-activated protein kinases are known to regu-
late apoptosis in various cancers. SB202190, an inhibi-
tor of p38, prevented 15d-PGJ2-induced activation of
caspase-8, -9, and -3 and significantly decreased apop-
tosis. PD98059, an inhibitor of MEK, significantly
increased sensitivity of the pancreatic cancer cells to
apoptosis (Hashimoto et al., 2004).
The role of EGF-signaling in chemoresistance has been
previously shown in ovarian cancer cells. The EGFR
ligand HB-EGF has been found to be upregulated in can-
cer cells and has been identified as an agent responsible
for invasion, angiogenesis, and chemoresistance (Miya-
moto et al., 2007). The cisplatin-resistant MCF-7 breast
cancer cells are characterized by increased EGFR phos-
phorylation, high levels of Akt activity, and Erk1 phos-
phorylation (Eckstein et al., 2008). These data are in good
agreement with our observation that FG cells stable
transfected with a vector bearing the EFEMP1 gene
exhibit enhanced chemoresistance, proliferation, and
inhibited apoptosis (Seeliger et al., 2009). We speculate
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that EFEMP1-induced activation of EGFR-signaling acti-
vating Akt and MAPK pathways could be responsible for
features of the EFEMP1 transfectants.
The issue of the effect of EFEMP1 overexpression on
angiogenesis is controversial. Angiogenesis is one step
of the pathogenic process of eye diseases caused by
mutation in the EFEMP1 gene. Accumulation of misfold-
ed mutant R345W EFEMP1 protein within the endo-
plasmic reticulum (ER) causes an activation of unfolded
protein response signaling and expression of ER stress-
responsive genes, including VEGF (Roybal et al., 2005).
Our previous data show that the cells overexpressing
EFEMP1 exhibit an enhanced angiogenetic potential in
comparison with the control cell line (Seeliger et al.,
2009). By contrast, it has been shown that constitutive
expression of EFEMP1 in the endothelial cells leads to
an inhibition of their invasion, proliferation, and sprouting
(Albig et al., 2006). Despite that we have not observed
any significant effect on the proliferation and apoptosis
on treatment of HUVECs (human umbilical vein endothe-
lial cells) with purified EFEMP1, our data are not in con-
tradiction with this study. We have found that VEGF
secretion is enhanced in FG cells overexpressing
EFEMP1 in comparison with the control cell line. This
implicates that not EFEMP1 directly but EFEMP1-
induced increased VEGF production is responsible for
proangiogenic phenotype of EFEMP1 transfectants.
Thus, our data presented in this study is in good agree-
ment with the observations described above. It has been
shown in L3.6pl cells that both the PI3K/Akt and p38
MAPK pathways are activated in a Src family kinase-
dependent manner on EGFR activation and are important
for EGF-mediated VEGF production in pancreatic cancer
cells (Summy et al., 2005). Therefore, we assume that the
described mechanism could explain the role of EFEMP1-
induced EGFR activation in enhancement of angiogene-
sis via increased VEGF secretion.
The data presented in this study show that EFEMP1
protein overexpressed in highly metastatic pancreas
carcinoma cell line L3.6pl binds to EGFR. EFEMP1
competes with EGF for receptor binding. EFEMP1 binds
to EGFR at the EGF binding site or in the close neigh-
borhood. This binding causes autophosphorylation of the
receptor in the positions Tyr-992 and Tyr-1068, but not in
the position Tyr-1068. Phosphorylation of EGFR leads to
activation of downstream signaling via Akt and MAPK.
This activation could be causative for the phenotype
observed in EFEMP1 overexpressing cells: enhancement
of proliferation, chemoresistance, and angiogenesis as
well as inhibition of apoptosis.
Materials and methods
Pancreatic cancer cell lines
The pancreatic cancer cell line FG is a variant of Colo375, a
human pancreatic adenocarcinoma cell line originally derived
from a celiac lymph node metastasis. L3.6pl is a highly meta-
static and angiogenic variant of FG selected by repeated injec-
tion of metastatic cells into the spleen and pancreas of mice.
Both cell lines were maintained in Dulbecco’s modified Eagle
Medium supplemented and under culture conditions as
described previously (Bruns et al., 1999).
Determination of concentration of EGF
Concentration of EGF in the original growth media or in the
media conditioned by both cell lines, respectively, was deter-
mined using a Human EGF Quantikine ELISA Kit (R&D Systems,
Minneapolis, USA) according to the manufacturer’s instruction
manual. The medium was conditioned by the same amounts of
FG or L3.6pl cells, respectively, for 48 h under the conditions of
the cell cultivation. Cell number was determined and the results
were calculated in pg/ml/106 cells.
Sequencing of EFEMP1-cDNA
To test whether the gene EFEMP1 is expressed in the cell lines
FG and L3.6pl in a wild type form or in a proangiogenic mutant
form (e.g., as mutant R345W), total RNA from both unstimulated
cell lines was isolated using a RNeasy mini kit (Qiagen, Hilden,
Germany). Total RNA was subjected to reverse transcription
followed by PCR using the SuperScriptIII One-Step RT-PCR
system with Platinum Taq High Fidelity (Invitrogen, Karlsruhe,
Germany) using gene-specific primers:
EFEMP1forw: 59-GAG GGG AGC AGT GCG TAG ACA;
EFEMP1rev: 59-TCG GCA CAT GGC ATT TGA GAC.
The expected 823 bp long PCR product was detected by
electrophoresis in 1% agarose gel with ethidium bromide stain-
ing. The PCR product was purified using a QIAquick PCR Puri-
fication Kit (Qiagen). Purified PCR product was sequenced by
Sequencing Service LaFuGa (Munich, Germany). Sequencing
data were edited and the sequence was compared with the pub-
lished EFEMP1 sequence using DNA* SeqMan and MegAlign
software (DNASTAR, Madison, USA).
Quantitative RT-PCR
To compare transcription of EFEMP1 in FG vs. L3.6pl cells,
quantitative real-time PCR and semi-quantitative RT-PCR was
applied to RNA extracted from both cell cultures using a RNeasy
kit (Qiagen). RNA integrity was verified by agarose-formaldehyde
electrophoresis detection of 18S and 28S rRNA, and isolated
RNA was quantified by spectrophotometry using the GeneQuant
Pro RNA/DNA calculator (Pharmacia, Freiburg, Germany). Quan-
titative RT-PCR for EFEMP1 was conducted using a Super-
ScriptIII Platinum SYBR green one-step qRT-PCR kit (Invitrogen)
with the EFEMP1 gene-specific primers EFEMP1up and
EFEMP1low (see above) according to the manufacturer’s
instructions on a LightCycler system (Roche Diagnostics, Mann-
heim, Germany). Typically, appropriate results were obtained
after 45 cycles. PCR efficiency was assessed using the plasmid
standards and quantified relative to the housekeeping gene tran-
script GAPDH. Sequences of the specific primers are as follows:
GAPDH forw: 59-GAG TCA ACG GAT TTG GTC GTA TTG GGC
G-39;
GAPDH rev: 59-GAC GCC TGC TTC ACC ACC TTC TTG ATG
TC-39;
EGF forw: 59-TGA TTT GCC CTG ACT CTA CTC CAC CC-39;
EGF rev: 59-GGC CTG CGA CTC CTC ACA TCT CTG-39;
EGFR forw: 59-CGC CCA GAC CGG ACG ACA GG-39;
EGFR rev: 59-CAC GGC GCC ATG CAG GAT TTC-39.
To test the size of the PCR product, semi-quantitative RT-PCR
was performed using the SuperScriptIII One-Step RT-PCR Sys-
tem with Platinum Taq High Fidelity (Invitrogen) using the same
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template and the same primer sets as in the case of real-time
RT-PCR.
Western blotting
Proteins from cell lysates or from immunoprecipitation were sep-
arated in SDS-PAGE gel with an appropriate concentration of
acrylamide/Bis to ensure optimal separation. Proteins were
transferred onto PVDF (polyvinylidene difluoride) membrane
Hybond P (Amersham/GE Healthcare, Uppsala, Sweden) via
semi-dry blotting. Efficient blotting was demonstrated by trans-
fer of the PeqGOLD prestained protein marker IV (PeqLab,
Erlangen, Germany). The membrane was then incubated for 1 h
at room temperature with Roti-Immunoblock buffer (Carl Roth,
Karlsruhe, Germany). After washing with TTBS (TBSq
0.5% Tween 20) buffer, the membrane was incubated with the
first antibody diluted in TTBS to the working concentration and
was incubated according to the manufacturer’s data. After
washing, the membrane was incubated with the HRP-labeled
second antibody (Dako, Glostrup, Denmark) diluted in blocking
buffer to the working concentration and incubated according to
the manufacturer’s data. After extensive washing, the bands
were visualized using ECL Plus Western blotting reagents and
Hyperfilm ECL (both from Amersham/GE Healthcare).
Co-immunoprecipitation of EFEMP1 and EGFR
Cell lysates were prepared from both cell lines L3.6pl and FG
using Complete Lysis-M buffer (Roche). The amount of lysate
was normalized to protein concentration assayed by a BSA
Protein Assay Kit (Pierce, Rockford, IL, USA). To deplete the
lysate on the proteins unspecifically bound to the agarose
beads, 200 ml of the lysate was incubated with protein G aga-
rose beads (Sigma-Aldrich, Munich, Germany; 20 ml of 50%
bead slurry) with gentle rocking for 1 h at 48C with no antibody
present. Preadsorbed lysates were incubated with gentle rock-
ing overnight at 48C. Then, 20 ml of 50% bead slurry of protein
G agarose and 10 mg anti-EGFR antibody was added. The sam-
ples were incubated with gentle rocking for 3 h at 48C and
washed 5 times with 500 ml of the cell lysis buffer. The pellet
was then resuspended with 20 ml 3= SDS Laemmli sample buf-
fer heated to 95–1008C for 5 min. Immunoprecipitated proteins
were separated into 15% SDS-PAGE gel, transferred onto PVDF
membrane and detected using anti-EFEMP1 antibody (Abcam,
Cambridge, UK) (see above).
EGF-EFEMP1 competition experiment
L3.6pl cells grown to 70% of apparent confluence were treated
with 50 ng/ml recombinant human EGF (R&D Systems) for
10 min at 378C or with the irrelevant protein BSA (albumin Frac-
tion V for molecular biology, Carl Roth) in parallel under the same
concentration and conditions. Cells were then subjected to co-
immunoprecipitation (see above) using anti-EGFR antibody.
Immunoprecipitation was analyzed by Western blotting using
anti-EFEMP1 antibody (Abcam). Loading was controlled by
Western blotting using anti-EGFR antibody (Cell Signaling,
Danvers, MA, USA).
Detection of EFEMP1-induced EGFR
phosphorylation
L3.6pl cells grown to 70% of apparent confluence were treated
with 50 ng/ml purified recombinant human EFEMP1 (Abnova,
Taipei City, Taiwan) for 48 h at 378C, or with the irrelevant protein
BSA (albumin Fraction V for molecular biology, Carl Roth) in par-
allel under the same concentration and conditions. Cell lysates
were prepared using Complete Lysis-M buffer (Roche) supple-
mented with sodium vanadate. The amount of lysate was nor-
malized to the protein concentration assayed by a BCA Protein
Assay Kit (Pierce). Cell lysates were then subjected to Western
blotting using a Phospho-EGF Receptor Antibody Sampler Kit
(Cell Signaling) according to the manufacturer’s instructionman-
ual. EFEMP1-dependent phosphorylation of EGFR at the posi-
tions Tyr-845, Tyr-992, Tyr-1045, and Tyr-1068 was assayed.
Antibody identifying total EGFR (Cell Signaling) was used as the
loading control.
FACE EGFR: in-cell Western analysis
for Tyr-992-phospho EGF
An assay was performed using a FACE EGFR Y992 kit (Active
Motif, Carlsbad, CA, USA) according to the manufacturer’s
instruction manual. A total of 10 000 FG or L3.6pl cells per well
were seeded on 96-well plates, starved for 24 h and then acti-
vated for 10 min at 378C with FCS or 40 ng/ml human recom-
binant EGF (R&D Systems), or were left untreated. Cells were
fixed by formaldehyde treatment and concentration of total
EGFR or its phosphorylated form was determined via conven-
tional ELISA. Wells containing the cells untreated with the first
antibody were used as a blank. Four wells were assayed for
each cell/treatment combination. Cell number was quantified
colorimetrically following staining with crystal violet. These data
were used for normalization of EGFR values to the cell number.
Statistical significance was analyzed using Student’s t-test.
Phosphorylation of the proteins downstream
to EGFR
Effect of EFEMP1 treatment on activation of Akt- and MAPK-
signal transduction pathways was investigated via detection of
Akt phosphorylation in the position Thr-308 and Erk1, Erk2
phosphorylation in positions Tyr-202 and Tyr-204. The cell
extracts prepared for studying EFEMP1-induced phosphoryla-
tion of EGFR (see above) were also used for investigation of the
downstream proteins. Anti-phospho-Akt (Thr-308) antibody and
anti-phospho-p44/42 MAPK (Thr-202/Tyr-204) (Cell Signaling)
identifying Akt or Erk1 and Erk2, respectively, were used for
Western blotting (see above).
Inhibition of EGFR activity via treatment
with PD15035
A fraction of the same cell culture used for phosphorylation
studies was treated with 50 ng/ml purified recombinant human
EFEMP1 (Abnova) and with or without 2 mmol/ml PD153035
(Tocris, Bristol, UK) (Xu and Shu, 2007). Cell extracts were pre-
pared (see above), normalized for protein concentration and
subjected to Western blotting using anti-phospho-Akt (Thr-308)
antibody and anti-phospho-p44/42 MAPK (Thr-202/Tyr-204).
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